Platelets play a central role in atherothrombotic events, which are responsible of major cardiovascular complications in human hypertension. 1 Nitric oxide (NO) inhibits multiple platelet functions via the activation of soluble guanylyl cyclase and the intracellular accumulation of the second messenger cyclic guanosine monophosphate (cGMP); 2,3 the same biochemical pathway is responsible for the NO-induced vascular smooth muscle cells relaxation. Thus, NO released by NO synthase type III in the vascular wall not only regulates vascular tone, but also contributes to maintain a nonthrombogenic surface of the vessel wall. 4 An impairment of the NO/cGMP system is a hallmark of endothelial dysfunction; this condition, associated with major cardiovascular risk factors, promotes key aspects of atherosclerosis, such as vasoconstriction, inflammation, and thrombosis. In human hypertension, endothelial dysfunction has been documented as a reduced endothelium-mediated relaxation in the peripheral and coronary vasculature 5, 6 that provides an adverse prognostic significance. 7 All components of the NO/cGMP pathway, including NO synthase type III and soluble guanylyl cyclase, have been identified in platelet cytoplasm; 3 the amount of NO released by human platelets has been estimated to be comparable to that of endothelial cells in resting conditions and even doubled in activated states. 8 Platelets, therefore, represent an accessible tissue model for functional studies of the NO/cGMP system, in alternative to endothelial and vascular smooth muscle cells.
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In human hypertension, controversial data are available about the platelet NO/cGMP system. On one hand, a reduced amount of NO in resting platelets 9 and decreased sensitivity to the NO synthase antagonist L-NG-monomethyl arginine in aggregating platelets 10 have been observed in hypertensive subjects compared to normotensive controls. On the other hand, similar amounts of more stable compound cGMP have been found in resting platelets from hypertensive subjects and normotensive controls. 11 Moreover, in human hypertension, no information is available about the clinical and hemodynamic determinants of the NO/cGMP activity in platelets.
In order to investigate this latter issue, we measured cGMP in resting platelets from a population of essential hypertensives (EHs) and examined the relationship between platelet cGMP and some clinical parameters as well as hemodynamic (blood pressure (BP), heart rate (HR), cardiac output assessed by impedance cardiography, and systemic vascular Background Platelets play a central role in atherothrombosis, which is responsible of major cardiovascular complications in human hypertension. nitric oxide (nO) inhibits platelet aggregation via the second messenger cyclic guanosine monophosphate (cGMP). In essential hypertensives (eHs), we examined the relationship between platelet cGMP and clinical, hemodynamic, humoral variables as well as the responses to aggregating agents.
Methods
In untreated eHs (male/female 106/43, age 44.4 ± 1.1 years, smokers yes/no 38/111), blood pressure (BP), heart rate (HR), and stroke volume (SV) (impedance cardiography) were assessed after supine rest and venous blood was sampled for platelet cGMP (radioimmunoassay on acid extracts of washed platelets), plasma cGMP, atrial natriuretic peptide (AnP), renin activity, aldosterone and platelet aggregation to epinephrine (ePI, 5 µmol/l), and adenosine diphosphate (ADP) (4 µmol/l) (optical aggregometry on platelet-rich plasma (PRP)).
results
Platelet cGMP (7.0 ± 0.3 pmol/10 9 cells, mean ± s.e.m.) was lower in males and smokers than in their counterparts (P < 0.01 for both). Among the variables tested, platelet cGMP was related to number of cigarettes (−0.21), high-density lipoprotein cholesterol (HDLc) (r = 0.32), aldosterone (r = −0.21), and hemoglobin (−0.16); in a multivariate analysis that also included sex, HDLc was the best predictor of platelet cGMP. The aggregating response to ePI (r = −0.28), but not to ADP (r = −0.07, ns), was inversely related to platelet cGMP levels. conclusions cGMP in resting platelets of eHs is positively predicted by HDLc and is inversely related to the aggregating response to ePI. It is suggested that a defect of the platelet nO/cGMP system could identify uncomplicated eHs at higher risk of thrombotic events during surges of sympathetic activity. articles Platelet cGMP in Human Hypertension resistances) and humoral (plasma renin activity (PRA), aldosterone, atrial natriuretic peptide (ANP), and plasma cGMP) variables.
As the NO/cGMP and sympathetic nervous system interact at multiple levels in the control of cardiovascular functions, 12 we also examined the relationship between cGMP in resting platelets of EHs and "ex vivo" aggregating responses to epinephrine (EPI), a physiological agonist of α 2 -adrenergic receptors on human platelets and to adenosine diphosphate (ADP), as comparing agent.
Methods
Population. The population study included 149 Caucasian subjects with essential hypertension, diagnosed on the basis of clinic BP >140/90 mm Hg recorded on at least two visits and a routine work-up aimed to exclude secondary hypertension, diabetes mellitus, renal failure, coronary artery disease, congestive heart failure, and acquired or congenital platelet disorders. The majority of the subjects were recently diagnosed, never treated hypertensives (>90%); in the minor group of treated patients, any pharmacological treatment, including antihypertensive agents, statins, or drugs interfering with platelet function, i.e., aspirin or nonsteroidal anti-inflammatory agents, was discontinued for at least 2 weeks before the study. An informed consent was obtained from all subjects and the study protocol was approved by the ethics committee of the institution.
Protocol. All studies were performed in the morning between 9 and 11 am in a warm (21 °C), quiet room; subjects were asked to refrain from smoking and drinking caffeine for the previous 12 h. After a 30-min supine rest, BP (by mercury sphygmomanometer) was measured every other minute and also the HR (by ECG) and stroke volume (SV, by impedance cardiography; BOMED NCCOM3 Medical Manufacturing, Irvine, CA) were monitored for 15 min. At the end, venous blood (45 ml) was sampled via a 19-gauge catheter previously positioned in a peripheral vein and maintained patient with saline infusion (1 ml/min). Hemodynamic measurements were averaged for the final analysis; SV was indexed to body surface area (SV i ); cardiac index (CO i ) was calculated as SV i × HR, and systemic vascular resistance index as mean BP/CO i × 80.
Assays
Platelet cGMP. Platelet cGMP was measured by radioimmunoassay on acid extracts of washed platelets. 13 In brief, peripheral venous blood (13 ml) was collected in EDTA 5 mmol/l, heparin 10 U/ml, sodium citrate 3.8% (9:1 vol/vol), and isobutylmethylxanthine (IBMX) 0.55 mmol/l and centrifuged at 200g for 20 min at 20 °C to obtain platelet-rich plasma (PRP). Then, the PRP was centrifuged at 1,000g for 10 min at 20 °C, the supernatant discarded, and pellet suspended in 550 µl modified Tyrode's solution (5 mmol/l HEPES and 0.35% bovine serum albumin, pH 7.4). After removing 50-µl aliquot for manual platelet count, the suspension was acid-precipitated with trichloroacetic acid (final concentration 6%) and centrifuged at 2,000g for 15 min at 4 °C. Pellet was discarded and supernatant washed with glacial ether (5×) to extract trichloroacetic acid and freezed at −40 °C until assayed. cGMP was assayed by radioimmunoassay with a commercial kit (RPR 525; Amersham International, Slough, UK). The intra-and interassay coefficients of variation were <10 and <15%, respectively. In normal controls (n = 30, age 38 ± 3 years, range 22-67 years), platelet cGMP was 6.9 ± 0.4 pmol/10 9 cells (mean ± s.e.m., range 3.6-15.2).
Blood assays. Venous blood (7 ml × 2) was collected in Na 2 EDTA 5 mmol/l tubes kept on ice (ANP, plasma cGMP) or at room temperature (PRA, Aldo); blood was centrifuged at 4 °C and plasma stored at −40 °C until assayed.
Plasma cGMP was measured by radioimmunoassay with a commercial kit, according to Sagnella et al. 14 (see platelet cGMP); plasma ANP was assessed by radioimmunoassay on C18 Sep-Pak cartridges (Waters Chromatography, Milford, MA) extracts with a commercial antiserum (α-h-ANP; Peninsula Laboratories Europe, Merseyside, UK) and a tracer (IM 185; Amersham International, Slough, UK). PRA and aldosterone were measured by radioimmunoassay with the help of commercial kits (Technogenetics-Recordati, Milano, Italy). Serum total cholesterol, high-density lipoprotein cholesterol (HDLc), triglycerides, glucose, electrolytes, creatinine, and red blood cells were measured by standardized automated methods; low-density lipoprotein cholesterol was calculated by Friedewald equation.
Platelet aggregation. Venous blood (9 ml × 2) was collected in sodium citrate (0.38% final concentration) and sequentially centrifuged at 200g for 20 min and 1,000g for 10 min to obtain PRP and platelet-poor plasma, respectively. Platelet aggregation to EPI 5 µmol/l and ADP 4 µmol/l (final concentration; Mascia Brunelli, Milano, Italy, for both) were tested on PRP (250 µl) in a two-channel optical aggregometer (Chronolog, Havertown, PA), according to Born's method. All experiments were performed within 120 min after blood collection. Platelet aggregation was expressed as the area under the curve (arbitrary units) of percent increments of light transmission during 8 min after EPI or ADP addition.
Statistical analysis. Data are expressed as means ± s.e.m.; analyses were performed by Statview version 4.1 (SAS Institute, Cary, NC). Humoral variables displaying right-skewed distributions (platelet and plasma cGMP, ANP, PRA, aldosterone) were logarithmically transformed. Statistical differences were assessed by one-way analysis of variance, followed by Bonferroni correction for multiple comparisons. The nonparametric Mann-Whitney test was used for comparisons within normal controls (males vs. females, smokers vs. nonsmokers) due to the small size of samples. Pearson's correlation was used to determine univariate associations between continuous variables. The multivariate linear regression analysis was used to identify independent predictors of variables. Statistical significance was set for P value ≤0.05. Hypertension grades 1, 2, and 3 were present in 41, 36, and 23% of the population study, respectively; clinical data are shown in Table 1 . In the supine position, the hemodynamic profile of EHs was characterized by increased systemic vascular resistance index ( Table 2) .
As for the humoral data ( Table 2) , mean platelet cGMP was not different from the normal controls (6.9 ± 0.4 pmol/10 9 cells, P = 0.93, ns) and was lower in hypertensive males compared to females (6.6 ± 0.3 pmol/10 9 cells vs. 8.0 ± 0.6 pmol/10 9 cells, P < 0.05), in smokers than nonsmokers (5.9 ± 0.4 pmol/10 9 cells vs. 7.4 ± 0.4 pmol/10 9 cells, P < 0.05). In normal controls (23 male/7 female, smoke yes/no = 11/19), platelet cGMP tended to be lower in males than females (6.6 ± 0.4 pmol/10 9 cells vs. 8.1 ± 0.5 pmol/10 9 cells, P < 0.05) and in smokers than nonsmokers (5.9 ± 0.4 pmol/10 9 cells vs. 7.6 ± 0.5 pmol/10 9 cells, P = 0.08).
In a univariate analysis, no relationship was found between platelet cGMP and the hemodynamic variables tested, including clinic systolic and diastolic BP ( Table 3) ; platelet cGMP was directly related to HDLc (Figure 1 ) and inversely to number of cigarettes, hemoglobin, and aldosterone plasma levels. Plasma cGMP and ANP were reciprocally related (r = 0.46, P < 0.01), but neither was related to platelet cGMP ( Table 3) . In a multivariate analysis, which also included sex ( Table 3) , HDLc was the best positive predictor of platelet cGMP in EHs (P < 0.01); it also explained platelet cGMP differences related to gender and smoking status, as HDLc was lower in hypertensive males than females (43.1 ± 1.1 mg/dl vs. 62.3 ± 2.2 mg/ dl, P < 0.001), in smokers than nonsmokers (43.8 ± 2.4 mg/dl vs. 50.3 ± 1.4 mg/dl, P < 0.05). Median HDLc value of 46 mg/dl identified two groups of EHs characterized by different platelet cGMP levels (5.8 ± 0.3 pmol/10 9 cells vs. 8.2 ± 0.4 pmol/10 9 cells, P < 0.001) (Figure 2 ) and similar low-density lipoprotein cholesterol values (138.0 ± 4.0 mg/dl vs. 143.4 ± 4.5 mg/dl, respectively, ns). articles
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Platelet aggregation
EPI 5 µmol/l was a weaker agonist than ADP 4 µmol/l (129 ± 11 arbitrary units vs. 243 ± 12 arbitrary units, P < 0.01). In a univariate analysis, the aggregating response to EPI was inversely related to platelet cGMP and directly related to age, systolic BP, systemic vascular resistance index, and platelet count; in a multivariate analysis, platelet cGMP was the best predictor of the aggregating response to EPI ( Table 4) . By dividing the population into three groups according to platelet cGMP levels (<5, from 5 to 10 and >10 pmol/10 9 cells, n = 24, 79, and 46, respectively), a blunted aggregating response to EPI was observed in the high-platelet cGMP group as compared to the intermediate and low groups (78.4 ± 16.4 arbitrary units vs. 129.3 ± 9.5 and 153 ± 12 arbitrary units, respectively, P < 0.01 vs. both) (Figure 3a) . The response to ADP was unrelated to platelet cGMP levels (r = −0.07, ns) and no differences were observed among the three groups (242 ± 19.0 arbitrary units vs. 251 ± 11.2 vs. 258 ± 11.4 arbitrary units, respectively, ns) (Figure 3b) .
discussion
There are two major findings of the present study in a population of EHs: first, the marker of NO activity cGMP in resting platelets spanned over a tenfold range and the levels were directly related to plasma HDLc, which was the best positive predictor of platelet cGMP among a number of clinical, hemodynamic, and humoral variables. Mean platelet cGMP in our uncomplicated, untreated EHs was not different from normal controls, as previously reported by Hoffman et al. 11 Second, functional finding of the study is that platelet cGMP in EHs was inversely related to platelet aggregation, as assessed by "ex vivo" aggregating responses to the physiological agonist EPI.
The specificity of platelet cGMP as a marker of NO activity may deserve a preliminary comment. cGMP mostly derives from the NO-activated soluble guanylyl cyclase in platelet cytosol, 15 as human platelets, at difference from endothelial cells, do not express ANP biologically active receptors coupled to particulate guanylyl cyclase. 16 Consistent with the experimental and clinical evidence 17 that cGMP in platelets and plasma represents two distinct pools, reflecting the activity of two major systems involved in cardiovascular regulation (NO and natriuretic peptides, respectively) is our present finding that plasma ANP was directly related to plasma cGMP, which mostly derives from endothelial cells, but was unrelated to platelet cGMP.
In our study, platelet cGMP was unrelated to BP over a wide range of values: this was true for systolic and diastolic, sitting, and supine BP; in addition, none of the hemodynamic variables assessed in supine EHs, namely cardiac output and systemic vascular resistances, showed a significant relationship articles
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with platelet cGMP. In a mixed population of normal subjects and treated coronary patients, 18 BP, age, and low-density lipoprotein cholesterol have been previously associated with an impaired release of NO, detected by a selective NO electrode in aggregating platelets. All these major cardiovascular risk factors were unexpectedly unrelated to cGMP levels in resting platelets of our EHs (Table 3) : the differences in experimental conditions and populations study likely explain the discrepancy between the studies. A defect of the endothelial NO/cGMP system characterizes the endothelial dysfunction, documented since the early phases of human hypertension as an impaired endotheliumdependent vasodilation. 5, 19 The degree of impairment of the endothelial NO/cGMP system in our EHs remains undefined, as endothelial function was not assessed by current available techniques, although a dissociation between the hemodynamic and antiplatelet effects of NO has been documented in humans, at least in a short-term study. 20 The hypothesis that hemodynamic factors primarily control the NO/cGMP system in endothelial cells, whereas the metabolic factors play a major role in platelets is supported by our finding that HDLc was the best predictor of platelet cGMP among the clinical, hemodynamic, and humoral variables tested. Circulating HDLc levels, indeed, were directly related to platelet cGMP (Figure 1 ) and in a multiple regression analysis also explained the differences in platelet cGMP related to gender and smoking status (Table 3) ; platelet cGMP, indeed, was 18 and 22% lower in hypertensive males and smokers, respectively, compared to their counterparts. Whether the relationship between HDLc and platelet cGMP is also present in the normotensive population, remains to be determined.
In isolated human platelets, HDLc has been shown to activate NO synthase 21 and to impair multiple platelet functions, in terms of decreased serotonin release, inhibition of the aggregating response to EPI, and reduced "ex vivo" thrombus formation. 22 In our hypertensive population, median HDLc value of 46 mg/dl identified two groups characterized by different platelet cGMP levels (Figure 2) . The two groups were not identified by other Adult Treatment Panel III criteria for metabolic syndrome, including overweight, as assessed by body mass index, and hypertriglyceridemia as well as by the full expression of the syndrome; in 28 subjects positive for at least three Adult Treatment Panel III criteria, in fact, platelet cGMP was similar to the remaining group (6.8 ± 0.6 pmol/10 9 cells vs. 7.0 ± 0.3 pmol/10 9 cells, respectively, ns).
HDLc in a multiple regression analysis also explained the inverse relationship between platelet cGMP and plasma aldosterone ( Table 3) : an interplay between the NO/cGMP system and HDLc in the inhibition of aldosterone secretion is supported by previous experimental 23 and clinical evidence. 24 The inverse relationship between plasma aldosterone and platelet cGMP, on the other hand, suggests that the in vitro dampening effect of aldosterone on platelet responses 25 is probably independent from the activation of a cGMP axis by mineralocorticoid/glucocorticoid receptors.
The variability of platelet cGMP was explained by HDLc for <10%; among the multiple variables affecting platelet cGMP levels, the role of hemoglobin should also be considered, as the inverse relationship between circulating hemoglobin and platelet cGMP (Table 3) suggests that the NO-scavenging effect of oxygenated hemoglobin documented in hemolytic disorders 26 also modulates NO bioavailability in clinical settings, apparently free from hematological diseases.
An antiplatelet effect of HDLc via the activation of the NO/cGMP system, as suggested by our data, may provide a pathogenetic mechanism for the relationship between dyslipidemia and increased thrombogenic potential 27 as well as for the protective effect of HDLc against recurrent venous thrombosis, documented in humans. 28 By this mechanism HDLc may contribute to cardiovascular protection, in addition to the classical antiatherogenic reverse cholesterol transport. 29 In support of this mechanism is our present finding that cGMP in resting platelets negatively modulates platelet function: "ex vivo" platelet aggregation in response to EPI, indeed, was blunted in the presence of high-platelet cGMP levels (Figure 3) . The blunting effect of cGMP on platelet aggregation was limited to the response to the weaker agonist EPI 5 µmol/l, as it was not observed with the stronger agonist ADP 4 µmol/l, at the standard doses used in optical aggregometry; the role of thromboxane B 2 in mediating the different responses remains to be determined. The aggregating response to epinephrine was almost halved in the high-platelet cGMP group compared to the low-platelet cGMP group; the response to the stronger agonist ADP was not different among the groups (means ± s.e.m., *P < 0.01 by AnOVA).
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Under experimental conditions of moderate, paraphysiological shear rate, EPI has been shown to enhance platelet aggregation at concentrations much lower than the 5 µmol/l tested in this study; interestingly, the synergistic effect of shearing on platelet activation could be demonstrated for EPI and not for ADP. 30 By interfering with the aggregating response to EPI, the platelet NO/cGMP system may prevent thrombotic events during surges of sympathetic activity, when 100-fold increments in plasma EPI have been documented.
An impaired NO production by human platelets has been documented to independently predict acute coronary syndromes, as platelet-derived NO is an autocrine regulator of the recruitment of platelets to the growing thrombus. 31 
limitations
The cross talk between cGMP and cAMP in the control of platelet function was not investigated; this point is of interest if we consider that platelets were isolated in the presence of IBMX, a nonselective inhibitor of the three phosphodiesterases involved in the catabolism of both nucleotides and that this compound has been shown to affect cAMP more than cGMP levels in human platelets. 32 The possibility that IBMX influenced our results, in that platelet cGMP values reflect a different sensitivity toward this compound and not necessarily cGMP levels in circulating platelets, should also be considered. In particular, a reduced sensitivity to IBMX in the low-platelet cGMP group and a synergism between IBMX and the weak agonist EPI could explain the enhanced aggregating response observed in these patients. A dual role for platelet cGMP, indeed, is supported by the growing evidence that low cGMP concentrations promote platelet activation/ secretion in response to subthreshold doses of agonists, whereas high cGMP levels inhibit platelet aggregation, thus, limiting the delayed responses and the size of platelet aggregates. 33 In conclusion, our cross-sectional study indicates that cGMP in resting platelets of EHs is directly related to HDLc and that a defect of the platelet NO/cGMP system may be associated with an enhanced "ex vivo" aggregating response to EPI. Prospective studies will prove whether this defect may identify EHs at higher risk of thrombotic events during surges of sympathetic activity.
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